Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

BACKGROUND: Metastatic melanoma is an incurable disease with an average survival of less than one year. Talabostat is a novel dipeptidyl peptidase inhibitor with immunostimulatory properties. METHODS: This phase II, open label, single arm study was conducted to evaluate the safety and efficacy of 75...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Eager, Robert M, Cunningham, C Casey, Senzer, Neil N, Stephenson, Joe, Anthony, Stephen P, O'Day, Steven J, Frenette, Gary, Pavlick, Anna C, Jones, Barry, Uprichard, Margaret, Nemunaitis, John
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2009
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2731782/
https://ncbi.nlm.nih.gov/pubmed/19643020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-263
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items